Editorial pass: filed as context: no real AI gain or problem (gain activity_only, problem absent).
The exact text we saved
This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.
TRUVACE RECORD VERSION record: TRV-2026-1209 version: 2 kind: revised reason: Editorial pass: filed as context: no real AI gain or problem (gain activity_only, problem absent). timestamp: 2026-11-04T09:55:40.652640Z status: published lens: general sector: health headline: Red Queen Bio is using AI to design antibodies for future viruses, WSJ says dek: OpenAI-backed Red Queen Bio uses AI to design antibodies against bird flu and future viruses, the WSJ reports. It has raised $36M in total. gain_title: AI is being used to design antibodies intended to target bird flu and other future viruses. problem_title: (none) trace_subject: (none) gain_reading: AI is being used to design antibodies intended to target bird flu and other future viruses. gain_evidence: uses AI to design antibodies against bird flu and future viruses problem_reading: (none) problem_evidence: (none) quick_read: On September 28, 2026, TNW reported on WSJ coverage of Red Queen Bio, an OpenAI-backed company that uses AI to design antibodies against bird flu and future viruses, and that has raised $36M in total. The development matters for pandemic preparedness because AI-designed antibodies could accelerate response to emerging threats, but the source provides no evidence of efficacy, safety testing, or deployment, leaving real-world impact unproven at the time of reporting. limitation: tag: Context key_points: Red Queen Bio is described as OpenAI-backed. | The company's stated application is designing antibodies against bird flu and future viruses. | The information is attributed to WSJ reporting, summarized by TNW. | The company has raised $36M in total according to the report. rundown: TNW summarized WSJ reporting on September 28, 2026 that Red Queen Bio is OpenAI-backed and focused on AI-designed antibodies. The brief report also notes financing, stating the company has raised $36M in total, but provides no technical details, timelines, or clinical validation data. sources: - journalism | TNW | https://thenextweb.com/news/red-queen-bio-ai-antibodies-openai-wsj | 2026-09-28 prev: bd02abfb5c67710390c33396f275e89efa3b6df8b22dbfb4d7e019304b6ba054
- SHA-256 hash
- 3624434b5db3f821fa25267607027db865f3a417868e377370497ad19d04b4e8
- Previous version’s hash
- bd02abfb5c67710390c33396f275e89efa3b6df8b22dbfb4d7e019304b6ba054
How to check it yourself, without trusting this page
Download any version from /api/record/TRV-2026-1209 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.
ace